meta|evidence oncology

Living systematic review and meta-analysis

metastatic/adv melanoma (mML)
mML - (neo)adjuvant (NA)
mML - NA - all population 9
mML - NA - PDL1 positive 1
mML - 1st line (L1)
mML - L1 - all population 7
mML - L1 - BRAF mutant 2
mML - L1 - BRAF wild 3
mML - 2nd line (L2)
mML - L2 - all population 11
mML - L2 - BRAF mutant 1
mesothelioma (MS)

immune chekpoint inhibitors
anti-CTLA-4
ipilimumab based treatment
ipilimumab alone
Ipilimumab (10 mg/kg)
anti-PD-(L)1
nivolumab based treatment
nivolumab alone
pembrolizumab based treatment
pembrolizumab alone
Immune checkpoint association
nivolumab plus ipilimumab

versus all
vs immune chekpoint inhibitors
vs anti-CTLA-4
vs ipilimumab based treatment
vs ipilimumab alone
vs Ipilimumab (10 mg/kg)
vs anti-PD-(L)1
vs nivolumab based treatment
vs nivolumab alone
vs Immunostimulant
vs interferon alpha
vs non active control
vs placebo

study list
mapping
overview
meta-analysis
forest plot
NMA
excluded

Study		Exclusion reasons	Remarks	Reference(s)
OpACIN-neo, 2019	-	not relevant outcome		Rozeman, E.A. The Lancet Oncology 2019; 20:948-. 10.1016/S1470-2045(19)30151-2

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -